ASH 2017 | Novel ALL treatment strategies: inotuzumab ozogamicin
Elias Jabbour
• 10 Dec 2017
Over the past year, several exciting new agents for the treatment of acute lymphoblastic leukemia (ALL) have been approved. In this interview, Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses one such agent, inotuzumab ozogamicin. Dr Jabbour highlights key data from the trial which led to the drug receiving breakthrough therapy designation (INO-VATE; NCT01564784), including response rates and MRD status. He emphasizes exciting ongoing studies of the drug in other settings, including in combination with low-dose chemotherapy and blinatumomab. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
